Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada

被引：1
|
作者：
Alahwal, Hatem [1 ]
Song, Kevin W. [2 ]
Duggan, Peter [3 ]
Sutherland, Heather J. [4 ]
Neri, Paola [5 ]
Broady, Raewyn [6 ]
Bahlis, Nizar J. [5 ,7 ]
Jimenez-Zepeda, Victor [3 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC, Canada
[2] Univ British Columbia, Div Hematol & Leukemia, BMT Program BC, Vancouver, BC, Canada
[3] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[4] BCCA, Vancouver, BC, Canada
[5] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[6] Univ British Columbia, Div Hematol, Leukemia BMT Program BC, Vancouver, BC, Canada
[7] Univ Calgary, Calgary, AB, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2131.2131
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2131
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Bortezomib with Dexamethasone in Newly Diagnosed Patients with Primary Systemic Light Chain Amyloidosis or Multiple Myeloma-Associated AL Amyloidosis
    Huang, Beihui
    Li, Juan
    Liu, Junru
    Zheng, Dong
    Chen, Mei
    Zhou, Zhenhai
    Xu, Duorong
    Zou, Waiyi
    BLOOD, 2012, 120 (21)
  • [32] Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis
    Jimenez-Zepeda, Victor H.
    Lee, Holly
    McCulloch, Sylvia
    Tay, Jason
    Duggan, Peter
    Neri, Paola
    Bahlis, Nizar
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2021, 28 (03): : 182 - 188
  • [33] Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
    Kenshi Suzuki
    Ashutosh D. Wechalekar
    Kihyun Kim
    Chihiro Shimazaki
    Jin Seok Kim
    Takayuki Ikezoe
    Chang-Ki Min
    Fude Zhou
    Zhen Cai
    Xiaonong Chen
    Shinsuke Iida
    Nagaaki Katoh
    Tomoaki Fujisaki
    Ho-Jin Shin
    NamPhuong Tran
    Xiang Qin
    Sandra Y. Vasey
    Brenda Tromp
    Brendan M. Weiss
    Raymond L. Comenzo
    Efstathios Kastritis
    Jin Lu
    Annals of Hematology, 2023, 102 : 863 - 876
  • [34] Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients
    G Palladini
    P Milani
    A Foli
    M Vidus Rosin
    M Basset
    F Lavatelli
    M Nuvolone
    L Obici
    S Perlini
    G Merlini
    Leukemia, 2014, 28 : 2311 - 2316
  • [35] Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
    Suzuki, Kenshi
    Wechalekar, Ashutosh D. D.
    Kim, Kihyun
    Shimazaki, Chihiro
    Kim, Jin Seok
    Ikezoe, Takayuki
    Min, Chang-Ki
    Zhou, Fude
    Cai, Zhen
    Chen, Xiaonong
    Iida, Shinsuke
    Katoh, Nagaaki
    Fujisaki, Tomoaki
    Shin, Ho-Jin
    Tran, NamPhuong
    Qin, Xiang
    Vasey, Sandra Y. Y.
    Tromp, Brenda
    Weiss, Brendan M. M.
    Comenzo, Raymond L. L.
    Kastritis, Efstathios
    Lu, Jin
    ANNALS OF HEMATOLOGY, 2023, 102 (4) : 863 - 876
  • [36] Melphalan Based Regimens for Treatment of Newly Diagnosed Amyloidosis, Lessons from Clinical Literature: A Systematic Review
    Ahmad, Muhaddis Ejaz
    Yousaf, Muhammad Abdullah
    Rafae, Abdul
    Malik, Mustafa Nadeem
    Syed, Tariq Iqtidar Sadiq
    Abdullah, Syed Maaz
    Khan, Maimoona
    Waheed, Asma
    Qamar, Fazeel
    Ibrahim, Ahmed
    Anwer, Faiz
    BLOOD, 2019, 134
  • [37] Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients
    Palladini, G.
    Milani, P.
    Foli, A.
    Rosin, M. Vidus
    Basset, M.
    Lavatelli, F.
    Nuvolone, M.
    Obici, L.
    Perlini, S.
    Merlini, G.
    LEUKEMIA, 2014, 28 (12) : 2311 - 2316
  • [38] Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center
    Victor H. Jimenez-Zepeda
    Holly Lee
    Nowell Fine
    Sylvia McCulloch
    Jason Tay
    Peter Duggan
    Paola Neri
    Nizar Bahlis
    Indian Journal of Hematology and Blood Transfusion, 2021, 37 : 675 - 678
  • [39] MUTLI-INSTITUTIONAL EXPERIENCE WITH UPFRONT CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CVD) IN THE TREATMENT OF AL AMYLOIDOSIS
    Venner, P.
    Jaccard, A.
    Hawkins, P.
    Roussel, M.
    Gibbs, S.
    Gillmore, J.
    Lachman, H.
    Whelan, C.
    Maramattom, L.
    Parameswaran, H.
    Comenzo, R.
    Wechalekar, A.
    HAEMATOLOGICA, 2012, 97 : 474 - 475
  • [40] Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center
    Jimenez-Zepeda, Victor H.
    Lee, Holly
    Fine, Nowell
    McCulloch, Sylvia
    Tay, Jason
    Duggan, Peter
    Neri, Paola
    Bahlis, Nizar
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2021, 37 (04) : 675 - 678
12345